文献速递精神分裂症与精神病性障碍

抗精神病药物与认知功能:系统综述与网络Meta分析

Antipsychotic Drugs and Cognitive Function: A Systematic Review and Network Meta-Analysis.
PubMed 文献 · JAMA Psychiatry · 2025-01-01

该系统综述与网络Meta分析纳入68项随机临床试验共9525例精神分裂症谱系障碍患者,比较不同抗精神病药物与安慰剂对认知总体评分的影响。结果显示,第一代多巴胺拮抗剂氟哌啶醇、氟奋乃静及氯氮平排名较低;无单个抗精神病药物优于安慰剂,但抗精神病药物作为一类整体与安慰剂相比有小的效应量优势。作者认为,当认知缺陷是关注点时,应避免使用第一代多巴胺拮抗剂和氯氮平。

要点

  • 第一代多巴胺拮抗剂氟哌啶醇、氟奋乃静及氯氮平在认知总体评分上排名较低。
  • 无单个抗精神病药物与安慰剂相比有明确更好的认知结局。
  • 抗精神病药物作为一类整体与安慰剂相比有小的效应量优势。

核心结论

  • 尽管数据相对稀疏,本综述结果提示当认知缺陷是关注点时,应避免使用第一代多巴胺拮抗剂和氯氮平。
  • 抗精神病药物不是促认知药物。
  • 与安慰剂相比的整体小幅优势可能由阳性症状较少伴随的思维紊乱减轻解释,而非真正意义上的认知缺陷改善。
  • 研究结果还提示,在随机临床试验中统一认知功能测量方法将是有益的。

研究设计与样本

  • 系统综述与随机效应频率学网络Meta分析,遵循PRISMA-NMA报告规范。
  • 检索Cochrane精神分裂症试验注册库至2023年6月25日。
  • 纳入68项随机临床试验,共9525例精神分裂症谱系障碍患者;平均(标准差)年龄35.1(8.9)岁;5878例男性(70%),2890例女性(30%);部分研究未提供此信息。

主要发现

  • 抗精神病药物之间差异不明确,但第一代多巴胺拮抗剂氟哌啶醇(标准化均数差[SMD] 0.04;95%CI -0.25至0.33)和氟奋乃静(SMD 0.15;95%CI -0.39至0.69)以及氯氮平(SMD 0.12;95%CI -0.23至0.48)排名较低。
  • 无单个抗精神病药物与安慰剂相比有明确更好的结局。
  • 抗精神病药物作为一类整体与安慰剂相比有小的效应量优势(平均SMD:肾上腺素能/低多巴胺能 -0.21;5-羟色胺能/多巴胺能 -0.26;毒蕈碱能 -0.28;多巴胺能 -0.40)。

关键数值与推荐

  • 主要结局为每项研究计算的认知总体评分变化。
  • 次要结局包括认知域、生活质量和功能。

临床怎么用

  • 作者认为,当认知缺陷是关注点时,应避免使用第一代多巴胺拮抗剂和氯氮平。
  • 作者认为,抗精神病药物不是促认知药物。
  • 作者认为,在随机临床试验中统一认知功能测量方法将是有益的。

局限性

  • 数据相对稀疏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cognitive deficits are a substantial part of the symptoms of schizophrenia spectrum disorders (SSDs) and contribute heavily to the burden of disease. Antipsychotic drugs are not cognitive enhancers, but due to their different receptor-binding profiles, they could differ in their effects on cognition. No previous network meta-analysis compared antipsychotics to placebo, which is important to determine whether use of these drugs is associated with cognitive performance in SSDs at all. OBJECTIVE: To determine the association of treatment with various antipsychotics and cognition in patients with SSDs. DATA SOURCES: Cochrane Schizophrenia Trials Register through June 25, 2023. STUDY SELECTION: Randomized clinical trials examining the effects on cognition of antipsychotic drugs or placebo in participants with SSD. DATA EXTRACTION AND SYNTHESIS: A systematic review and random-effects frequentist network meta-analysis was performed following Preferred Reporting Items for Systematic Reviews and Meta-analyses-Network Meta-analysis reporting guideline. MAIN OUTCOMES AND MEASURES: The primary outcome was change in overall cognition score calculated for each study. Secondary outcomes included cognitive domains, quality of life, and functioning. RESULTS: This study included 68 studies involving 9525 participants (mean [SD] age, 35.1 [8.9] years; 5878 male [70%] and 2890 [30%] female; some studies did not provide this information). There were few clear differences between antipsychotics, but first-generation dopamine antagonists haloperidol (standardized mean difference [SMD], 0.04; 95% CI, -0.25 to 0.33) and fluphenazine (SMD, 0.15; 95% CI, -0.39 to 0.69) as well as clozapine (SMD, 0.12; 95% CI, -0.23 to 0.48) ranked low. No individual antipsychotic was associated with a clearly better outcome than placebo, but antipsychotics as a group were, with small effect sizes (mean SMDs: adrenergic/low dopamine, -0.21; serotonergic/dopaminergic, -0.26; muscarinic, -0.28; dopaminergic, -0.40). CONCLUSION AND RELEVANCE: Although data are relatively sparse, those reviewed in this study suggest that first-generation dopamine antagonists and clozapine should be avoided when cognitive deficits are a concern. Antipsychotics are not procognitive drugs. The overall small superior outcomes compared to placebo may be explained by less disordered thought patterns associated with fewer positive symptoms rather than cognitive deficits in the proper sense. The findings also suggest that harmonizing measurement of cognitive function in randomized clinical trials would be beneficial.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Feber L, Peter NL, Chiocchia V, et al. Antipsychotic Drugs and Cognitive Function: A Systematic Review and Network Meta-Analysis. JAMA Psychiatry. 2025. PMID: 39412783. doi:10.1001/jamapsychiatry.2024.2890

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。